Definitive Nanoparticle Dissolution Testing

DATE
April 15, 2021
TIME
11:00 a.m. EDT, 8:00 a.m. PDT, 5:00 p.m. CEST, 4:00 p.m. BST - Duration: 60 Minutes

Overview

One of the major challenges in modern drug development is the poor aqueous solubility of many drug candidates. Nanoparticle formulations are an attractive solution to increase the bioavailability of drugs with low aqueous solubility. Dissolution testing is one of the most important methods used to characterize the expected in vivo bioavailability under in vitro conditions. Thus, an efficient dissolution method is necessary during the nanoparticle development process to facilitate the selection of lead formulations with an expected higher bioavailability. It is equally important for quality control purposes during later stages of the product life cycle. Furthermore, automation of dissolution testing with nanoparticles facilitates faster method transfer to the quality control lab.

In this webinar, we will introduce you to the Agilent NanoDis System. Designed in collaboration with Dr. Emre Türeli from nanoparticle manufacturer MyBiotech GmbH, the NanoDis System enables R&D formulation chemists to deliver new formulations into manufacturing faster, and also allows manufacturing teams to deliver consistent batches of QC-released drug products ready for commercial sale—all in an automated and compliant manner.

Brought to you by:
Agilent Technologies

Speakers

Karen Krauel-Göllner, Ph.D.
Product Manager,
Agilent Technologies
Jeff Huber
Contributing Editor,
C&EN Media Group

Registration

Agilent wants to keep in touch with you. Please let us know your preference.

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) via email, in accordance with the ACS Privacy Policy.

© 2025 American Chemical Society, 1155 16th St NW, Washington, DC 20036, USA. View our Privacy Policy